NCT06291311 Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
| NCT ID | NCT06291311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | HPV Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-12-27 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-12-27 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria for NIPP treatment * Age ≥ 18 years * mRNA or DNA-based virus detection by smear (also external findings) * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 * Written informed consent to participate in the study * Inclusion criteria for control group * Age ≥ 18 years * Swab-based mRNA or DNA-based virus detection (also external findings) * Clearly visible transformation zone of the cervix corresponding to T1/T2 * Written informed consent to participate in the study Exclusion criteria: The following exclusion criteria apply to both groups of patients (NIPP treatment and control group). * Transformation zone not fully visible * Evidence of invasive disease * Serious cardiovascular diseases
Contact & Investigator
Martin Weiss, Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital Tuebingen
Frequently Asked Questions
Who can join the NCT06291311 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying HPV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06291311 currently recruiting?
Yes, NCT06291311 is actively recruiting participants. Contact the research team at martin.weiss@med.uni-tuebingen.de for enrollment information.
Where is the NCT06291311 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT06291311 clinical trial?
NCT06291311 is sponsored by University Hospital Tuebingen. The principal investigator is Martin Weiss, Dr. med. at University Hospital Tuebingen. The trial plans to enroll 50 participants.